Orifarm makes changes in production
Orifarm wants to be even more competitive in its 13 countries. For this reason, the Danish pharmaceutical company has, among other things, analyzed the possibilities for its production in Denmark.
“We can succeed if we have a clear competitive advantage in scale, portfolio or unique capacities that together give our customers and patients the best opportunities . We have analyzed nine separate criteria, including CSR, quality, delivery reliability, cost, capacity, short- and long-term investment needs, production capacity and product portfolio. As a result of this review and in order to strengthen our product portfolio, maintain our competitiveness and deliver reliable supply, we have decided to transfer our products, manufactured in our Viminco site in Skælskør, Denmark, to our Hobro site, also in Denmark,” Erik Sandberg, CEO in Orifarm, says.
Orifarm will now have one large production unit in Denmark instead of two small units. Orifarm also has production in Poland.
“This means that we are expanding in Hobro, while we unfortunately will have to close our good production in Skælskør. The latter we will do during the next year and a half in a proper way in collaboration with the 130 skilled employees in Skælskør,” says Erik Sandberg.
He underlines that it has been a very difficult decision because the managers and employees of Viminco have all done an excellent job for Orifarm for many years.
For further information, pls. contact Martin Broberg, Vice President Communications, Orifarm, here: firstname.lastname@example.org